Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00011-021-01473-y http://scihub22266oqcxt.onion/10.1007/s00011-021-01473-y 34086061!8176665!34086061     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Inflamm+Res 2021 ; 70 (8): 877-889 Nephropedia Template TP {{tp|p=34086061|t=2021. The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications |pdf=|usr=}}{{34086061}} gab.com Text The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications JO: Inflamm Res http://www.kidney.de/pget.php?&tw=1&pmid=34086061 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, known as coronavirus disease 2019 (COVID-19) causes cytokine release syndrome (CRS), leading to acute respiratory distress syndrome (ARDS), acute kidney and cardiac injury, liver dysfunction, and multiorgan failure. Although several studies have discussed the role of 5-lipoxygenase (5-LOX) in viral infections, such as influenzae and SARS, it remains unexplored in the pathophysiology of COVID-19. 5-LOX acts on free arachidonic acid (AA) to form proinflammatory leukotrienes (LTs). Of note, numerous cells involved with COVID-19 (e.g., inflammatory and smooth muscle cells, platelets, and vascular endothelium) widely express leukotriene receptors. Moreover, 5-LOX metabolites induce the release of cytokines (e.g., tumour necrosis factor-alpha [TNF-alpha], interleukin-1alpha [IL-1alpha], and interleukin-1beta [IL-1beta]) and express tissue factor on cell membranes and activate plasmin. Since macrophages, monocytes, neutrophils, and eosinophils can express lipoxygenases, activation of 5-LOX and the subsequent release of LTs may contribute to the severity of COVID-19. This review sheds light on the potential implications of 5-LOX in SARS-CoV-2-mediated infection and the anticipated therapeutic role of 5-LOX inhibitors. Twit Text FOAVip The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications ????Inflamm Res http://www.kidney.de/pget.php?&tw=1&pmid=34086061 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34086061 #FOAvip English Wikipedia <ref>{{Cite pmid|34086061}}</ref> The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications #MMPMID34086061 Ayola-Serrano NC; Roy N; Fathah Z; Anwar MM; Singh B; Ammar N; Sah R; Elba A; Utt RS; Pecho-Silva S; Rodriguez-Morales AJ; Dhama K; Quraishi S Inflamm Res 2021[Aug]; 70 (8): 877-889 PMID34086061show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, known as coronavirus disease 2019 (COVID-19) causes cytokine release syndrome (CRS), leading to acute respiratory distress syndrome (ARDS), acute kidney and cardiac injury, liver dysfunction, and multiorgan failure. Although several studies have discussed the role of 5-lipoxygenase (5-LOX) in viral infections, such as influenzae and SARS, it remains unexplored in the pathophysiology of COVID-19. 5-LOX acts on free arachidonic acid (AA) to form proinflammatory leukotrienes (LTs). Of note, numerous cells involved with COVID-19 (e.g., inflammatory and smooth muscle cells, platelets, and vascular endothelium) widely express leukotriene receptors. Moreover, 5-LOX metabolites induce the release of cytokines (e.g., tumour necrosis factor-alpha [TNF-alpha], interleukin-1alpha [IL-1alpha], and interleukin-1beta [IL-1beta]) and express tissue factor on cell membranes and activate plasmin. Since macrophages, monocytes, neutrophils, and eosinophils can express lipoxygenases, activation of 5-LOX and the subsequent release of LTs may contribute to the severity of COVID-19. This review sheds light on the potential implications of 5-LOX in SARS-CoV-2-mediated infection and the anticipated therapeutic role of 5-LOX inhibitors. |*COVID-19 Drug Treatment[MESH] |*SARS-CoV-2[MESH] |Animals[MESH] |Arachidonate 5-Lipoxygenase/*metabolism[MESH] |Arachidonic Acid/metabolism[MESH] |COVID-19/*enzymology/*physiopathology[MESH] |Cytokine Release Syndrome[MESH] |Cytokines/metabolism[MESH] |Enzyme Inhibitors/pharmacology[MESH] |Humans[MESH] |Inflammation[MESH] |Interleukins/*metabolism[MESH] |Leukotrienes/metabolism[MESH] |Lipoxygenase Inhibitors/*pharmacology[MESH] |Treatment Outcome[MESH]The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its (epmc).pdf DeepDyve Pubget Overpricing